IMU product line - HER-Vaxx, page-9

The last update I have on Hervaxx after emailing the company around September 23.

Next Horizon Trial to date has not gone well as they were unable to recruit sufficient eligible patients. Being that; By the time patients qualify for the trial (having failed 2-3 previous lines of treatment) they are often too unwell to go on the trial and sadly pass away within a couple of months.

This is while they moved the trial to Taiwan and expanded the trial sights greatly.

When I pushed them on guidance as to when the Phase 2 study would be completed by and how patients have they dosed to date. They avoid the question directly and said the trial should be completed by end of H1 2024. (original guidance was July 2023).

I'm not sure what transpired at the AGM as I was unable to attend, but there appears to be a lot of renewed chatter about a commercial deal in coming.

I would have to agree with Fourdollars and challenge this notion. The original phase 2 Horizon trial data read out was greater then 2 years ago. And snice then nothing new has been released. Just a few poster presentations off the same old data set. (By contrast we are seeing blow by blow updates on Azercel and Vaxinia)

Everyone knows what the Hervaxx results were Big Pharma inclusive. And although promising, if it was sufficient to get a commercial deal done we would have seen it by now.

There is a glimmer of hope for Hervaxx the company can finish the Next Horizon trial and table a new data set set post July 2024. But the fact the company has removed Hervaxx as a valuation inflection point on its investor presentations IMO tells you everything you need to know.

Not investment advice - DYOR